Targeted Medical Pharma, Inc. (TMP), also doing business as Physician Therapeutics (PTL), is a specialty pharmaceutical company that develops and commercializes amino acid-based medications. The Company develops and distributes a line of amino acid-based medical food products, dietary supplements and generic drugs to physicians, pharmacies and patients throughout the United States and abroad. The Company operates through TMP, Complete Claims Processing Inc. (CCPI) and Amino Nutritionals segments. TMP develops and distributes amino acid-based therapeutic products and distributes pharmaceutical products from other manufacturers. CCPI segment provides point-of-care dispensing solutions, and billing and collections services. Amino Nutritionals segment develops and distributes amino acid-based dietary supplements directly to consumers. Its products and services include Medical Foods, Medical foods and generic pharmaceuticals, and Billing and Collections.
Industry, Sector and Symbol:
Average Prices:- 52 Week Range: $0.01 - $0.03
P/E:- Trailing P/E Ratio:
- Foreward P/E Ratio: -0.24
- P/E Growth:
Sales & Book Value:- Annual Revenue: $5.26 million
- Price / Sales: 0.06
- Book Value: ($0.47) per share
- Price / Book: -0.02
Profitability:Misc:- Average Volume: 2,702 shs.
- Beta: -2.85
Frequently Asked Questions for Targeted Medical Pharma (OTCMKTS:TRGM)
What is Targeted Medical Pharma's stock symbol?
Targeted Medical Pharma trades on the OTCMKTS under the ticker symbol "TRGM."
Who are some of Targeted Medical Pharma's key competitors?
Some companies that are related to Targeted Medical Pharma include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Medtronic PLC (MDT), AbbVie (ABBV), Bayer AG (BAYRY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY) and Abbott Laboratories (ABT).
Who are Targeted Medical Pharma's key executives?
Targeted Medical Pharma's management team includes the folowing people:
- Kim Giffoni, Chief Executive Officer, Director
- William B. Horne, Chief Financial Officer
- Douglas P. Gintz, Chief Technology Officer
- David Samuel Silver M.D., Chief Medical Officer, Director
- Kerry N. Weems, Non-Executive Chairman of the Board, Director
- Maurice J. DeWald, Independent Director
- Thomas Wenkart, Independent Director
How do I buy Targeted Medical Pharma stock?
Shares of Targeted Medical Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Targeted Medical Pharma's stock price today?
One share of Targeted Medical Pharma stock can currently be purchased for approximately $0.01.
MarketBeat Community Rating for Targeted Medical Pharma (OTCMKTS TRGM)MarketBeat's community ratings are surveys of what our community members think about Targeted Medical Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Targeted Medical Pharma (OTCMKTS:TRGM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Targeted Medical Pharma (OTCMKTS:TRGM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Targeted Medical Pharma (OTCMKTS:TRGM)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Targeted Medical Pharma (OTCMKTS:TRGM)Current Year EPS Consensus Estimate: $-0.11000 EPS
Next Year EPS Consensus Estimate: $-0.04000 EPS
Dividend History for Targeted Medical Pharma (OTCMKTS:TRGM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Targeted Medical Pharma (OTCMKTS:TRGM)Insider Ownership Percentage: 69.20%
Insider Trades by Quarter for Targeted Medical Pharma (OTCMKTS:TRGM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/24/2015 | Kim Giffoni | CEO | Sell | 8,580 | $0.02 | $171.60 |  |
| 5/28/2014 | William Shell | CEO | Sell | 2,000 | $0.60 | $1,200.00 | |
| 5/27/2014 | William Shell | CEO | Sell | 3,000 | $0.65 | $1,950.00 | |
| 4/10/2014 | William Shell | CEO | Sell | 150,000 | $0.60 | $90,000.00 | |
| 4/9/2014 | Kim Giffoni | EVP | Buy | 5,000 | $0.83 | $4,150.00 | |
| 12/12/2013 | Kim Giffoni | EVP | Buy | 1,000 | $0.90 | $900.00 | |
| 12/11/2013 | Kim Giffoni | EVP | Buy | 11,980 | $0.88 | $10,542.40 | |
| 12/2/2013 | Kim Giffoni | EVP | Buy | 4,800 | $1.06 | $5,088.00 | |
| 9/13/2013 | William Shell | Director | Sell | 2,000 | $0.84 | $1,680.00 | |
| 6/20/2013 | William Shell | Director | Buy | 28,100 | $1.15 | $32,315.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Targeted Medical Pharma (OTCMKTS:TRGM)
Latest Headlines for Targeted Medical Pharma (OTCMKTS:TRGM)
| Source: |
|
| Date | Headline |
|---|
 | Targeted Medical Pharma Finalizes Exclusive Agreement for Distribution in China
au.finance.yahoo.com - January 13 at 1:00 PM |
| TARGETED MEDICAL PHARMA, INC. Financials
finance.yahoo.com - December 8 at 1:18 PM |
| Targeted Medical Pharma Breaks Ground in the Consumer Goods Market
finance.yahoo.com - December 3 at 1:00 PM |
| TARGETED MEDICAL PHARMA, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 13 at 5:19 PM |
| TARGETED MEDICAL PHARMA, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements
biz.yahoo.com - October 1 at 3:14 PM |
| New Research from Targeted Medical Pharma Finds a Link Between Obesity and Nutritional Deficiencies
finance.yahoo.com - April 27 at 3:00 PM |
| TARGETED MEDICAL PHARMA, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 15 at 6:07 AM |
| Tauriga Sciences, Inc. Expands Agreement with Targeted Medical Pharma, Inc.
finance.yahoo.com - March 4 at 7:45 AM |
| TARGETED MEDICAL PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 3 at 4:06 PM |
| TARGETED MEDICAL PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
biz.yahoo.com - February 27 at 6:42 PM |
| Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan
au.finance.yahoo.com - February 19 at 1:00 PM |
Targeted Medical Pharma (TRGM) Chart for Thursday, July, 27, 2017
